A detailed history of Royal Bank Of Canada transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 7,058 shares of CCCC stock, worth $42,348. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,058
Previous 23,850 70.41%
Holding current value
$42,348
Previous $194,000 83.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$4.05 - $8.1 $68,007 - $136,015
-16,792 Reduced 70.41%
7,058 $32,000
Q1 2024

May 15, 2024

BUY
$5.3 - $11.0 $123,527 - $256,377
23,307 Added 4292.27%
23,850 $194,000
Q4 2023

Feb 14, 2024

SELL
$1.18 - $6.03 $6,207 - $31,723
-5,261 Reduced 90.64%
543 $3,000
Q3 2023

Nov 14, 2023

BUY
$1.81 - $3.89 $9,491 - $20,399
5,244 Added 936.43%
5,804 $10,000
Q2 2023

Aug 14, 2023

SELL
$2.75 - $3.77 $6,525 - $8,946
-2,373 Reduced 80.91%
560 $1,000
Q1 2023

May 15, 2023

SELL
$3.1 - $9.02 $16,594 - $48,284
-5,353 Reduced 64.6%
2,933 $9,000
Q4 2022

Feb 14, 2023

BUY
$5.42 - $10.24 $39,181 - $74,024
7,229 Added 683.92%
8,286 $48,000
Q3 2022

Nov 14, 2022

BUY
$8.03 - $12.77 $2,224 - $3,537
277 Added 35.51%
1,057 $9,000
Q2 2022

Aug 15, 2022

SELL
$5.06 - $26.46 $8,480 - $44,346
-1,676 Reduced 68.24%
780 $6,000
Q1 2022

May 16, 2022

SELL
$19.99 - $33.23 $180,289 - $299,701
-9,019 Reduced 78.6%
2,456 $60,000
Q4 2021

Feb 14, 2022

BUY
$29.39 - $46.86 $113,151 - $180,411
3,850 Added 50.49%
11,475 $369,000
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $87,907 - $123,624
2,448 Added 47.29%
7,625 $341,000
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $157,329 - $218,365
5,177 New
5,177 $196,000

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $293M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.